Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cardiovascular Therapeutics

• Publication date

  2011-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1755-5922.2010.00134.xPMID 21749674
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of Residues in the 558-Loop of Factor VIIIa A2 Subunit That Interact with Factor IXa*

  2009cited by this paper
• F9 Malmö, factor IX and deep vein thrombosis

  2009cited by this paper
• Activation mechanisms of coagulation factor IX

  2009cited by this paper
• Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention

  2008cited by this paper
• Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study

  2008cited by this paper
• Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex.

  2008cited by this paper
• Mechanisms of thrombus formation.

  2008cited by this paper
• A randomized, repeat‐dose, pharmacodynamic and safety study of an antidote‐controlled factor IXa inhibitor

  2008cited by this paper
• Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia.

  2008cited by this paper
• The Nature of the Stable Blood Clot Procoagulant Activities*

  2008cited by this paper
• Gene variants associated with deep vein thrombosis.

  2008cited by this paper
• Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

  2008cited by this paper
• Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII).

  2008cited by this paper
• Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B

  2007cited by this paper
• Segregation of Platelet Aggregatory and Procoagulant Microdomains in Thrombus Formation: Regulation by Transient Integrin Activation

  2007cited by this paper
• In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.

  2007cited by this paper
• Thrombus organization and healing in the swine experimental aneurysm model. Part I. A histological and molecular analysis.

  2007cited by this paper
• Snake-venom-derived Factor IX-binding protein specifically blocks the gamma-carboxyglutamic acid-rich-domain-mediated membrane binding of human Factors IX and X.

  2007cited by this paper
• Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition

  2007cited by this paper
• PAR-1-stimulated factor IXa binding to a small platelet subpopulation requires a pronounced and sustained increase of cytoplasmic calcium.

  2006cited by this paper
• Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII.

  2006cited by this paper
• The interface between the EGF2 domain and the protease domain in blood coagulation factor IX contributes to factor VIII binding and factor X activation.

  2006cited by this paper
• Cutaneous wound healing is impaired in hemophilia B.

  2006cited by this paper
• Genetic determinants of normal variation in coagulation factor (F) IX levels: genome‐wide scan and examination of the FIX structural gene

  2006cited by this paper
• A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway

  2006cited by this paper
• First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology: A Phase 1a Pharmacodynamic Evaluation of a Drug-Antidote Pair for the Controlled Regulation of Factor IXa Activity

  2006cited by this paper
• The influence of sodium ion binding on factor IXa activity

  2006cited by this paper
• A C-type lectin-like protein from Agkistrodon acutus venom binds to both platelet glycoprotein Ib and coagulation factor IX/factor X.

  2005cited by this paper
• Plaque Instability Frequently Occurs Days or Weeks Before Occlusive Coronary Thrombosis: A Pathological Thrombectomy Study in Primary Percutaneous Coronary Intervention

  2005cited by this paper
• Structural Determinants of Factor IX(a) Binding in Nitrophorin 2, a Lipocalin Inhibitor of the Intrinsic Coagulation Pathway*

  2005cited by this paper
• Down-regulation of Factor IXa in the Factor Xase Complex by Protein Z-dependent Protease Inhibitor*

  2005cited by this paper
• Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa.

  2004cited by this paper
• Antidote-mediated control of an anticoagulant aptamer in vivo

  2004cited by this paper
• Identification of Residues Asn89, Ile90, and Val107 of the Factor IXa Second Epidermal Growth Factor Domain That Are Essential for the Assembly of the Factor X-activating Complex on Activated Platelets*

  2004cited by this paper
• Crystal Structure of the Calcium-stabilized Human Factor IX Gla Domain Bound to a Conformation-specific Anti-factor IX Antibody*

  2004cited by this paper
• Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system

  2004cited by this paper
• The Significance of Circulating Factor IXa in Blood*

  2004cited by this paper
• The dynamics of thrombin formation.

  2003cited by this paper
• Decreased mortality of ischaemic heart disease among carriers of haemophilia.

  2003cited by this paper
• A Human Antibody That Inhibits Factor IX/IXa Function Potently Inhibits Arterial Thrombosis Without Increasing Bleeding

  2002cited by this paper
• Pharmacokinetic and pharmacodynamic modeling of humanized anti–factor IX antibody (SB 249417) in humans

  2002cited by this paper
• Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke

  2002cited by this paper
• Calcium‐binding analysis and molecular modeling reveal echis coagulation factor IX/factor X‐binding protein has the Ca‐binding properties and Ca ion‐independent folding of other C‐type lectin‐like proteins

  2002cited by this paper
• RNA aptamers as reversible antagonists of coagulation factor IXa

  2002cited by this paper
• Does Inflammatory Proteolytic Activity Contribute to the Increased Factor IX Activation Peptide in Men at High Risk of Coronary Heart Disease? A Preliminary Study

  2002cited by this paper
• Intrinsic pathway of blood coagulation contributes to thrombogenicity of atherosclerotic plaque.

  2002cited by this paper
• Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X

  2001cited by this paper
• Inhibition of Arterial Thrombosis by a Soluble Tissue Factor Mutant and Active Site-blocked Factors IXa and Xa in the Guinea Pig

  2001cited by this paper
• Factor IX and thrombosis

  2001cited by this paper
• Hydrophobic Contact between the Two Epidermal Growth Factor-like Domains of Blood Coagulation Factor IX Contributes to Enzymatic Activity*

  2000cited by this paper
• Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis.

  2000cited by this paper
• Activation of Clotting Factors XI and IX in Patients With Acute Myocardial Infarction

  2000cited by this paper
• Zymogen factor IX potentiates factor IXa-catalyzed factor X activation.

  2000cited by this paper
• Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.

  2000cited by this paper
• A Human Antibody that Binds to the γ-carboxyglutamic Acid Domain of Factor IX Is a Potent Antithrombotic In Vivo

  1999cited by this paper
• Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity.

  1999cited by this paper
• Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.

  1999cited by this paper
• Targeted Inhibition of Intrinsic Coagulation Limits Cerebral Injury in Stroke without Increasing Intracerebral Hemorrhage

  1999cited by this paper
• Inhibition of the generation of thrombin and factor Xa by a fucoidan from the brown seaweed Ecklonia kurome.

  1999cited by this paper
• Surface Loop 199–204 in Blood Coagulation Factor IX Is a Cofactor-dependent Site Involved in Macromolecular Substrate Interaction*

  1999cited by this paper
• Neutrophil elastase cleavage of human factor IX generates an activated factor IX-like product devoid of coagulant function.

  1998cited by this paper
• Nitrophorin-2: a novel mixed-type reversible specific inhibitor of the intrinsic factor-X activating complex.

  1998cited by this paper
• Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog.

  1998cited by this paper
• Blood Coagulation Factor IX Residues Glu78 and Arg94 Provide a Link between Both Epidermal Growth Factor-like Domains That Is Crucial in the Interaction with Factor VIII Light Chain*

  1998cited by this paper
• Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass.

  1998cited by this paper
• Relative Efficacy of Active Site-Blocked Factors IXa, Xa in Models of Rabbit Venous and Arterio-Venous Thrombosis

  1997cited by this paper
• EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY I. ILLUSTRATIVE REFERENCE RANGES BY AGE, SEX AND HORMONE USE

  1997cited by this paper
• Interaction of Factor IXa with Factor VIIIa

  1997cited by this paper
• Structure, recognition and adaptive binding in RNA aptamer complexes.

  1997cited by this paper
• Human Factor IX Binds to Specific Sites on the Collagenous Domain of Collagen IV*

  1997cited by this paper
• Identification of the Phospholipid Binding Site in the Vitamin K-dependent Blood Coagulation Protein Factor IX*

  1996cited by this paper
• Increased Activation of the Haemostatic System in Men at High Risk of Fatal Coronary Heart Disease

  1996cited by this paper
• Activation peptide of human factor IX has oligosaccharides O-glycosidically linked to threonine residues at 159 and 169.

  1994cited by this paper
• The activation of human blood coagulation factor X on the surface of endothelial cells: a comparison with various vascular cells, platelets and monocytes

  1994cited by this paper
• First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa.

  1994cited by this paper
• The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X.

  1993cited by this paper
• Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.

  1993cited by this paper
• The active site of factor IXa is located far above the membrane surface and its conformation is altered upon association with factor VIIIa. A fluorescence study.

  1992cited by this paper
• Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

  1991cited by this paper
• The coagulation cascade: initiation, maintenance, and regulation.

  1991cited by this paper
• In vitro selection of RNA molecules that bind specific ligands

  1990cited by this paper
• Comparative interactions of factor IX and factor IXa with human platelets.

  1989cited by this paper
• Nucleotide sequence of the gene for human factor IX (antihemophilic factor B).

  1985cited by this paper
• The gene structure of human anti‐haemophilic factor IX.

  1984cited by this paper
• Binding of factors IX and IXa to cultured vascular endothelial cells.

  1983cited by this paper
• Amino‐terminal sequence of human factor IX: Presence of γ‐carboxyl glutamic acid residues

  1976cited by this paper
• Amino-terminal sequence of human factor IX: presence of gamma-carboxyl glumatic acid residues.

  1976cited by this paper

• In silico Structural Analysis of Truncated 2’ Fluoro-RNA Aptamer: Elucidating EGF-1 and EGF-2 Binding Domains on Factor IX Protein

  2021cites this paper
• Factor VIIa and Factor IXa Inhibitors as Anticoagulants: A Review

  2017cites this paper
• New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism

  2017cites this paper
• Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target

  2016cites this paper
• Titrating haemophilia B phenotypes using siRNA strategy: evidence that antithrombotic activity is separated from bleeding liability

  2015cites this paper
• UvA-DARE ( Digital Academic Repository ) Factor XI as target for antithrombotic therapy

  2014cites this paper
• An update on recent patents on thrombin inhibitors (2010 – 2013)

  2014cites this paper
• Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway?

  2013influential citation
• Co-morbidity in adult haemophilia patients

  2012cites this paper
• Factor XI as target for antithrombotic therapy

  year unknowncites this paper
• Factor XI as target for antithrombotic therapy

  year unknowncites this paper